| __timestamp | Gilead Sciences, Inc. | Rhythm Pharmaceuticals, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 2983000000 | 1213000 |
| Thursday, January 1, 2015 | 3426000000 | 3425000 |
| Friday, January 1, 2016 | 3398000000 | 6311000 |
| Sunday, January 1, 2017 | 3878000000 | 9518000 |
| Monday, January 1, 2018 | 4056000000 | 28080000 |
| Tuesday, January 1, 2019 | 4381000000 | 36550000 |
| Wednesday, January 1, 2020 | 5151000000 | 46125000 |
| Friday, January 1, 2021 | 5246000000 | 68486000 |
| Saturday, January 1, 2022 | 5673000000 | 92032000 |
| Sunday, January 1, 2023 | 6090000000 | 117532000 |
| Monday, January 1, 2024 | 6091000000 |
Unveiling the hidden dimensions of data
In the ever-evolving pharmaceutical industry, understanding the financial strategies of leading companies is crucial. Over the past decade, Gilead Sciences, Inc. and Rhythm Pharmaceuticals, Inc. have shown contrasting trends in their Selling, General, and Administrative (SG&A) expenses. From 2014 to 2023, Gilead Sciences has seen a steady increase in SG&A expenses, growing by approximately 104%, reflecting its expansive market strategies and operational scale. In contrast, Rhythm Pharmaceuticals, a smaller player, has experienced a staggering increase of over 9,600% in the same period, indicating aggressive growth and investment in market penetration. This divergence highlights the different stages and strategies of these companies within the pharmaceutical landscape. As Gilead consolidates its market position, Rhythm is rapidly scaling its operations, offering a fascinating glimpse into the dynamics of pharmaceutical financial management.
SG&A Efficiency Analysis: Comparing Pfizer Inc. and Rhythm Pharmaceuticals, Inc.
Selling, General, and Administrative Costs: Gilead Sciences, Inc. vs Neurocrine Biosciences, Inc.
Who Optimizes SG&A Costs Better? Gilead Sciences, Inc. or Intra-Cellular Therapies, Inc.
Breaking Down SG&A Expenses: Gilead Sciences, Inc. vs Axsome Therapeutics, Inc.
Cost Management Insights: SG&A Expenses for Gilead Sciences, Inc. and Opthea Limited
Selling, General, and Administrative Costs: Gilead Sciences, Inc. vs Xenon Pharmaceuticals Inc.
Teva Pharmaceutical Industries Limited or Rhythm Pharmaceuticals, Inc.: Who Manages SG&A Costs Better?
Cost Management Insights: SG&A Expenses for Corcept Therapeutics Incorporated and Rhythm Pharmaceuticals, Inc.
Breaking Down SG&A Expenses: Rhythm Pharmaceuticals, Inc. vs MorphoSys AG
Rhythm Pharmaceuticals, Inc. or Arrowhead Pharmaceuticals, Inc.: Who Manages SG&A Costs Better?
Who Optimizes SG&A Costs Better? Rhythm Pharmaceuticals, Inc. or ImmunityBio, Inc.
Rhythm Pharmaceuticals, Inc. and Galapagos NV: SG&A Spending Patterns Compared